Loading...

RVL Pharmaceuticals plc

RVLPNASDAQ
HealthcareBiotechnology
$0.03
$-0.01(-32.05%)

RVL Pharmaceuticals plc (RVLP) Company Profile & Overview

Explore RVL Pharmaceuticals plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

RVL Pharmaceuticals plc (RVLP) Company Profile & Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

SectorHealthcare
IndustryBiotechnology
CEOMr. Brian A. Markison

Contact Information

908 809 1300
400 Crossing Boulevard, Bridgewater, NJ, 08807

Company Facts

125 Employees
IPO DateOct 19, 2018
CountryUS

Frequently Asked Questions